US EditionSelvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025
Summary by The AI Journal
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
SelvitaReposted by 
The AI Journal
The AI JournalSelvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025
Krakow, Poland – March 27, 2025 – Selvita S.A. [WSE: SLV], one of Europe’s leading preclinical CROs, has announced its financial results for 2024 and provided an update on its backlog for 2025. Key Highlights: In Q4 2024, Selvita generated EUR 22.5 million in commercial revenues, marking a 14% year-over-year increase. EBITDA reached EUR 4.8 million, up 26% y/y1,2, with an EBITDA margin of 21.1%, compared to 14.1% in the first three quarters of …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
